

Amendments to the Specification:

**Please replace pages 8-10, 8a, 9a, and 10a, with the following:**

- (i) the text of pages 8a, 9a, and 10a; then
- (ii) the text of lines 24-29 of original page 9; then
- (iii) the text of original page 10.

**Please amend the paragraph beginning at page 8a, line 2, as follows:**

This invention refers to the use of an adenovirus defective in its VAI and VAII virus-associated RNAs ~~for the production of a pharmaceutical composition~~ for the treatment of cancer.

**Please amend the paragraph beginning at page 8a, line 6, as follows:**

It also refers to the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has a mutation in the sequences of the VAI and VAII RNA genes.

**Please amend the paragraph beginning at page 8a, line 10, as follows:**

Another objective of the invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has a mutation in the sequences of the genes that control the expression of the VAI and VAII RNA genes.

**Please amend the paragraph beginning at page 8a, line 15, as follows:**

Another objective of the invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has mutations in the VA RNA genes in one or more genes of the group E1a, E1b, and E4 to obtain selective replication in tumors.

**Please amend the paragraph beginning at page 8a, line 21, as follows:**

Another objective of the invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has mutations in the VA RNA genes and promoters that regulate one or more genes in the group E1a, E1b, and E4 to obtain selective replication in tumors.

**Please amend the paragraph beginning at page 8a, line 27, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has mutations in the VA RNA genes to obtain selective replication in tumor cells with an active Ras pathway or unresponsive to the action of interferon.

**Please amend the paragraph beginning at page 9a, line 4, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has mutations in the VA RNA genes to obtain selective replication in tumor cells and modifications in its capsid to increase its infectivity or to direct it to a receptor present on a tumor cell.

**Please amend the paragraph beginning at page 9a, line 11, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus has mutations in the VA RNA genes that confer selective replication on tumor cells and that, in turn, contain other genes commonly used in the field of cancer gene therapy such as prodrug activators, tumor suppressors, or immunostimulants.

**Please amend the paragraph beginning at page 9a, line 19, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus is a human

adenovirus derived from a serotype between 1 and 50 with genetic mutations in the VA RNAs genes that confer selective replication on tumor cells.

**Please amend the paragraph beginning at page 9a, line 25, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus is a human adenovirus derived from serotype 5.

**Please amend the paragraph beginning at page 10a, line 1, as follows:**

Yet another objective of this invention is the use of an adenovirus ~~for the production of a pharmaceutical composition~~ for the treatment of cancer wherein said adenovirus is a mutant adenovirus dl331.